Aquestive Therapeutics, Inc. AQST Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s deferred revenue, net of current portion?
- Aquestive Therapeutics, Inc. (AQST) reported deferred revenue, net of current portion of $19.12M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s deferred revenue, net of current portion changed year-over-year?
- Aquestive Therapeutics, Inc.'s deferred revenue, net of current portion decreased by 3.2% year-over-year, from $19.74M to $19.12M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s deferred revenue, net of current portion has grown at a 39.8% compound annual growth rate (CAGR), from $3.63M to $19.39M.